Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 64
Filtrer
1.
J Prim Care Community Health ; 15: 21501319241263223, 2024.
Article de Anglais | MEDLINE | ID: mdl-39077980

RÉSUMÉ

BACKGROUND: Early detection of autism spectrum disorder (ASD) has the potential to significantly reduce the impact of the condition, however previous reviews have found little evidence to support screening programs for ASD in young children. METHODS: We conducted a review with the aim of updating evidence on 3 aspects: (a) diagnostic stability of ASD in young children; (b) accuracy of ASD screening tools in young children; and (c) the benefits of early interventions in screen-detected young children with ASD. RESULTS: A total of 33 studies were included in our review. Five studies looking at diagnostic stability reported estimates ranging from 71.9% to 100%, however the majority only included a follow-up of 24 months and all studies raised concerns regarding the risk of bias due particularly to lack of blinding, sample size, and patient flow. A total of 25 studies, reported in 26 articles, were identified that reported accuracy data on 11 screening tools. Most of the reports were concerned with versions of M-CHAT, reporting sensitivity estimates from 0.67 to 1.0; however, many of these were deemed to be of high risk of bias due to lack of blinding and follow-up. Four studies reported on early interventions in screen-detected children; however, the majority did not find significant improvements on the relevant outcomes. CONCLUSIONS: Overall, the evidence on screening for ASD in young children captured by this review is not conclusive regarding the 3 aspects of screening in this population. Future studies should attempt to ensure blinded diagnostic assessments, include longer follow-up periods and limit attrition.


Sujet(s)
Trouble du spectre autistique , Dépistage de masse , Humains , Trouble du spectre autistique/diagnostic , Enfant d'âge préscolaire , Dépistage de masse/méthodes , Diagnostic précoce , Nourrisson , Enfant
2.
J Cardiovasc Electrophysiol ; 35(6): 1150-1155, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38566579

RÉSUMÉ

INTRODUCTION: Proactive esophageal cooling has been FDA cleared to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency (RF) cardiac ablation procedures. Data suggest that procedure times for RF pulmonary vein isolation (PVI) also decrease when proactive esophageal cooling is employed instead of luminal esophageal temperature (LET) monitoring. Reduced procedure times may allow increased electrophysiology (EP) lab throughput. We aimed to quantify the change in EP lab throughput of PVI cases after the introduction of proactive esophageal cooling. METHODS: EP lab throughput data were obtained from three EP groups. We then compared EP lab throughput over equal time frames at each site before (pre-adoption) and after (post-adoption) the adoption of proactive esophageal cooling. RESULTS: Over the time frame of the study, a total of 2498 PVIs were performed over a combined 74 months, with cooling adopted in September 2021, November 2021, and March 2022 at each respective site. In the pre-adoption time frame, 1026 PVIs were performed using a combination of LET monitoring with the addition of esophageal deviation when deemed necessary by the operator. In the post-adoption time frame, 1472 PVIs were performed using exclusively proactive esophageal cooling, representing a mean 43% increase in throughput (p < .0001), despite the loss of two operators during the post-adoption time frame. CONCLUSION: Adoption of proactive esophageal cooling during PVI ablation procedures is associated with a significant increase in EP lab throughput, even after a reduction in total number of operating physicians in the post-adoption group.


Sujet(s)
Ablation par cathéter , Oesophage , Veines pulmonaires , Humains , Oesophage/chirurgie , Ablation par cathéter/effets indésirables , Facteurs temps , Veines pulmonaires/chirurgie , Veines pulmonaires/physiopathologie , Résultat thérapeutique , Hypothermie provoquée , Facteurs de risque , Durée opératoire , Techniques électrophysiologiques cardiaques , Flux de travaux , Études rétrospectives , Fibrillation auriculaire/chirurgie , Fibrillation auriculaire/physiopathologie , Fibrillation auriculaire/diagnostic , Mâle
4.
J Am Geriatr Soc ; 71(2): 394-403, 2023 02.
Article de Anglais | MEDLINE | ID: mdl-36273408

RÉSUMÉ

BACKGROUND: In older patients with atrial fibrillation (AF), cognitive impairment and frailty are prevalent. It is unknown whether the risk and benefit of anticoagulation differ by cognitive function and frailty. METHODS: A total of 1244 individuals with AF with age ≥65 years and a CHADSVASC score ≥2 were recruited from clinics in Massachusetts and Georgia between 2016 and 18 and followed until 2020. At baseline, frailty status and cognitive function were assessed. Hazard ratios of anticoagulation on physician adjudicated outcomes were adjusted by the propensity for receiving anticoagulation and stratified by cognitive function and frailty status. RESULTS: The average age was 75.5 (± 7.1) years, 49% were women, and 86% were prescribed oral anticoagulants. At baseline, 528 (42.4%) participants were cognitively impaired and 172 (13.8%) were frail. The adjusted hazard ratios of anticoagulation for the composite of major bleeding or death were 2.23 (95% confidence interval: 1.08-4.61) among cognitively impaired individuals and 0.94 (95% confidence interval: 0.49-1.79) among cognitively intact individuals (P for interaction = 0.08). Adjusted hazard ratios for anticoagulation were 1.84 (95% confidence interval: 0.66-5.13) among frail individuals and 1.39 (95% confidence interval: 0.84-2.40) among not frail individuals (P for interaction = 0.67). CONCLUSION: Compared with no anticoagulation, anticoagulation is associated with more major bleeding episodes and death in older patients with AF who are cognitively impaired.


Sujet(s)
Fibrillation auriculaire , Fragilité , Accident vasculaire cérébral , Humains , Femelle , Sujet âgé , Mâle , Fibrillation auriculaire/complications , Fibrillation auriculaire/traitement médicamenteux , Fragilité/complications , Personne âgée fragile , Facteurs de risque , Anticoagulants/usage thérapeutique , Hémorragie , Cognition , Accident vasculaire cérébral/prévention et contrôle , Accident vasculaire cérébral/complications
5.
Cell Death Dis ; 13(12): 1042, 2022 12 15.
Article de Anglais | MEDLINE | ID: mdl-36522328

RÉSUMÉ

Nuclear actin participates in a continuously expanding list of core processes within eukaryotic nuclei, including the maintenance of genomic integrity. In response to DNA damage, nuclear actin polymerises into filaments that are involved in the repair of damaged DNA through incompletely defined mechanisms. We present data to show that the formation of nuclear F-actin in response to genotoxic stress acts as a scaffold for PML NBs and that these filamentous networks are essential for PML NB fission and recruitment of microbodies to DNA lesions. Further to this, we demonstrate that the accumulation of the toxic lamin A precursor prelamin A induces mislocalisation of nuclear actin to the nuclear envelope and prevents the establishment of nucleoplasmic F-actin networks in response to stress. Consequently, PML NB dynamics and recruitment to DNA lesions is ablated, resulting in impaired DNA damage repair. Inhibition of nuclear export of formin mDia2 restores nuclear F-actin formation by augmenting polymerisation of nuclear actin in response to stress and rescues PML NB localisation to sites of DNA repair, leading to reduced levels of DNA damage.


Sujet(s)
Actines , Protéines nucléaires , Actines/génétique , Protéines nucléaires/génétique , Corps nucléaires de la leucémie promyélocytaire , Noyau de la cellule , Altération de l'ADN , ADN , Protéine de la leucémie promyélocytaire/génétique
6.
Environ Res ; 214(Pt 4): 114081, 2022 11.
Article de Anglais | MEDLINE | ID: mdl-35973463

RÉSUMÉ

Despite the growing problem of anxiety and depression amongst young people aged 14-24 years living in urban settings, reviews about the role of exposure to green and blue spaces or nature in preventing anxiety and depression tend to focus on children, adults or sometimes adolescents. This review aims to explore whether exposure to green and blue spaces reduces the risk of anxiety and depression among young people aged 14-24 years living in urban settings and provide a conceptual framework. The academic databases CINAHL plus, Global Health, MEDLINE, ProQuest: Dissertations and Theses, PsycINFO, Scopus and OpenGrey were searched for research published in English between January 2000 and June 2020. All study designs were eligible. All included studies were assessed for quality. Searches identified 9208 sources with 48 meeting the inclusion criteria for the review. Experimental studies provided evidence that walking or being in a green space improves mood and state anxiety immediately following the intervention. Non-randomised evaluations and observational studies suggest that social interaction, physical activity, and mindfulness mediate the relationship between exposure to green space and mental health. We propose that the absence of noise and restorative qualities of green spaces promotes mindfulness and interrupt rumination, which in turn reduce the risk of anxiety disorders and depression. This review and the resulting conceptual framework provide evidence to healthcare professionals about the value of contact with nature and green social prescribing. For policymakers, it provides evidence about the value of bringing the benefits of forests, vegetation and nature into cities, and ensuring that these spaces are accessible and safe for young people to use.


Sujet(s)
Anxiété , Dépression , Adolescent , Adulte , Anxiété/prévention et contrôle , Troubles anxieux , Enfant , Dépression/prévention et contrôle , Personnel de santé , Humains , Santé mentale
7.
J Gen Intern Med ; 37(15): 3893-3899, 2022 11.
Article de Anglais | MEDLINE | ID: mdl-35102482

RÉSUMÉ

BACKGROUND: In older patients with atrial fibrillation (AF), physical, cognitive, and psychosocial limitations are prevalent. The prognostic value of these conditions for major bleeding is unclear. OBJECTIVE: To determine whether geriatric conditions are prospectively associated with major bleeding in older patients with AF on anticoagulation. DESIGN: Multicenter cohort study with 2-year follow-up from 2016 to 2020 in Massachusetts and Georgia from cardiology, electrophysiology, and primary care clinics. PARTICIPANTS: Diagnosed with AF, age 65 years or older, CHA2DS2-VASc score of 2 or higher, and taking oral anticoagulant (n=1,064). A total of 6507 individuals were screened. MAIN MEASURES: A six-component geriatric assessment of frailty, cognitive function, social support, depressive symptoms, vision, and hearing. Main outcome was major bleeding adjudicated by a physician panel. KEY RESULTS: At baseline, participants were, on average, 75.5 years old and 49% were women. Mean CHA2DS2-VASc score was 4.5 and the mean HAS-BLED score was 3.3. During 2.0 (± 0.4) years of follow-up, 95 (8.9%) participants developed an episode of major bleeding. After adjusting for key covariates and accounting for competing risk from death, cognitive impairment (hazard ratio [HR] 1.62, 95% confidence interval [CI]: 1.02-2.56) and frailty (HR 2.77, 95% CI 1.38-5.58) were significantly associated with the development of major bleeding. CONCLUSIONS: In older patients with AF taking anticoagulants, cognitive impairment and frailty were independently associated with major bleeding.


Sujet(s)
Fibrillation auriculaire , Fragilité , Accident vasculaire cérébral , Humains , Femelle , Sujet âgé , Mâle , Fibrillation auriculaire/complications , Fibrillation auriculaire/diagnostic , Fibrillation auriculaire/traitement médicamenteux , Anticoagulants/effets indésirables , Fragilité/complications , Fragilité/diagnostic , Fragilité/épidémiologie , Pronostic , Études de cohortes , Appréciation des risques , Facteurs de risque , Hémorragie/induit chimiquement , Hémorragie/épidémiologie , Hémorragie/complications
8.
BMC Cardiovasc Disord ; 21(1): 319, 2021 06 30.
Article de Anglais | MEDLINE | ID: mdl-34193076

RÉSUMÉ

BACKGROUND: Since the early descriptions of large series of accessory atrioventricular pathway ablations in adults and adolescents over 20 years ago, there have been limited published reports based on more recent experiences of large referral centers. We aimed to characterize accessory pathway distribution and features in a large community-based population that influence ablation outcomes using a tiered approach to ablation. METHODS: Retrospective analysis of 289 patients (age 14-81) who underwent accessory ablation from 2015-2019 was performed. Pathways were categorized into anteroseptal, left freewall, posteroseptal, and right freewall locations. We analyzed patient and pathway features to identify factors associated with prolonged procedure time parameters. RESULTS: Initial ablation success rate was 94.7% with long-term success rate of 93.4% and median follow-up of 931 days. Accessory pathways were in left freewall (61.6%), posteroseptal (24.6%), right freewall (9.6%), and anteroseptal (4.3%) locations. Procedure outcome was dependent on pathway location. Acute success was highest for left freewall pathways (97.1%) with lowest case times (144 ± 68 min) and fluoroscopy times (15 ± 19 min). Longest procedure time parameters were seen with anteroseptal, left anterolateral, epicardial-coronary sinus, and right anterolateral pathway ablations. CONCLUSIONS: In this community-based adult and adolescent population, majority of the accessory pathways are in the left freewall and posteroseptal region and tend to be more easily ablated. A tiered approach with initial use of standard ablation equipment before the deployment of more advance tools, such as irrigated tips and 3D mapping, is cost effective without sacrificing overall efficacy.


Sujet(s)
Faisceau accessoire atrioventriculaire/chirurgie , Troubles du rythme cardiaque/chirurgie , Ablation par cathéter/tendances , Services de santé communautaires/tendances , Prestation intégrée de soins de santé/tendances , Types de pratiques des médecins/tendances , Irrigation thérapeutique/tendances , Faisceau accessoire atrioventriculaire/diagnostic , Faisceau accessoire atrioventriculaire/économie , Faisceau accessoire atrioventriculaire/physiopathologie , Potentiels d'action , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Troubles du rythme cardiaque/diagnostic , Troubles du rythme cardiaque/économie , Troubles du rythme cardiaque/physiopathologie , Ablation par cathéter/effets indésirables , Ablation par cathéter/économie , Prise de décision clinique , Services de santé communautaires/économie , Analyse coût-bénéfice , Prestation intégrée de soins de santé/économie , Femelle , Coûts des soins de santé/tendances , Rythme cardiaque , Humains , Mâle , Adulte d'âge moyen , Durée opératoire , Types de pratiques des médecins/économie , Études rétrospectives , Irrigation thérapeutique/effets indésirables , Irrigation thérapeutique/économie , Facteurs temps , Résultat thérapeutique , Jeune adulte
10.
Rev Esp Cardiol (Engl Ed) ; 74(11): 943-952, 2021 Nov.
Article de Anglais, Espagnol | MEDLINE | ID: mdl-33127317

RÉSUMÉ

INTRODUCTION AND OBJECTIVES: Data are scarce on outcomes of transvenous lead removal (TLR) in adult congenital heart disease (CHD). We evaluated the safety of the TLR procedure in adult CHD patients from a 10-year national database. METHODS: We used the Healthcare Cost and Utilization Project Nationwide Inpatient Sample to identify TLR procedures in adult patients with and without CHD from 2005 to 2014. Outcomes included in-hospital mortality and complications. RESULTS: Of 132 068 adult patients undergoing TLR, 1939 had simple CHD, 657 had complex CHD, and 626 had unclassified CHD. The number of TLR procedures in adult CHD slightly increased from 236 in 2005 to 445 in 2014, with fluctuations over the study period. The overall rate of any complications in the TLR procedure was 16.6% in patients with CHD vs 10.1% in patients without CHD (P <.001). In a propensity score-matched cohort, CHD was associated with a higher risk of any complication after full adjustment vs patients without CHD (adjusted odd ratio, 1.49; 95% confidence interval, 1.11-1.99; P=.007). Simple and complex CHD were associated with 1.5- and 2.1-fold increased risks of any TLR-related complication, respectively. CHD was not associated with an increased risk of in-hospital mortality (adjusted odd ratio, 0.77; 95% confidence interval, 0.42-1.39; P=.386). CONCLUSIONS: Compared with patients without CHD, adult patients with simple and complex CHD undergoing TLR are more likely to have complications but show no increase in mortality.


Sujet(s)
Cardiopathies congénitales , Adulte , Bases de données factuelles , Cardiopathies congénitales/épidémiologie , Mortalité hospitalière , Humains , Odds ratio , Études rétrospectives
11.
J Am Heart Assoc ; 9(6): e014108, 2020 03 17.
Article de Anglais | MEDLINE | ID: mdl-32146898

RÉSUMÉ

Background Direct-acting oral anticoagulant (DOAC) dosing guidelines for atrial fibrillation recommend dose alteration based on age, renal function, body weight, and drug-drug interactions. There is paucity of data describing the frequency and factors associated with prescription of potentially inappropriate doses. Methods and Results In the ongoing SAGE-AF (Systematic Assessment of Geriatric Elements in Atrial Fibrillation) study, we performed geriatric assessments (frailty, cognitive impairment, sensory impairments, social isolation, and depression) for participants with atrial fibrillation (age ≥65 years, CHA2DS2VASc ≥2, no anticoagulant contraindications). We developed an algorithm to analyze DOAC dose appropriateness accounting for drug-drug interactions, age, renal function, and body weight. We also examined whether geriatric impairments were related to inappropriate dosing. Of 1064 patients prescribed anticoagulants, 460 received a DOAC. Participants were aged 74±7 years, 49% were women, and 82% were white. A quarter (23%; n=105) of participants received inappropriate DOAC dose, of whom 82 (78%) were underdosed and 23 (22%) were overdosed. Among participants receiving an inappropriate dose, 12 (11%) were identified using the drug-drug interactions criteria and would have otherwise been misclassified. In multivariable regression analyses, older age, higher CHA2DS2VASc score, and history of renal failure were associated with inappropriate DOAC dosing (P<0.05). Geriatric conditions were not associated with inappropriate dosing. Conclusions In this cohort, over 20% of older patients with atrial fibrillation treated with DOACs were prescribed an inappropriate dose, with most being underdosed. Drug-drug interactions were common. Factors that influence prescription of guideline-nonadherent doses may be perception of higher bleeding risk or presence of renal failure in addition to lack of familiarity with dosing guidelines.


Sujet(s)
Fibrillation auriculaire/traitement médicamenteux , Techniques d'aide à la décision , Inhibiteurs du facteur Xa/administration et posologie , Prescription inappropriée , Types de pratiques des médecins , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Fibrillation auriculaire/diagnostic , Calcul des posologies , Interactions médicamenteuses , Mauvais usage des médicaments prescrits , Inhibiteurs du facteur Xa/effets indésirables , Femelle , Géorgie , Évaluation gériatrique , Hémorragie/induit chimiquement , Humains , Mâle , Massachusetts , Sécurité des patients , Polypharmacie , Études prospectives , Appréciation des risques , Facteurs de risque , Résultat thérapeutique
12.
Front Cardiovasc Med ; 6: 155, 2019.
Article de Anglais | MEDLINE | ID: mdl-31737647

RÉSUMÉ

Background: Geriatric conditions are common among patients with atrial fibrillation (AF) and relate to complications of oral anticoagulation (OAC). Objective: To examine the prevalence of geriatric conditions among older patients with AF on OAC and relate type of OAC to geriatric conditions. Methods: Participants had a diagnosis of AF, were aged ≥65 years, CHA2DS2VASC ≥ 2, and had no OAC contraindications. Participants completed a 6-component geriatric assessment that included validated measures of frailty (CHS Frailty Scale), cognitive function (MoCA), social support (MOS), depressive symptoms (PHQ9), vision, and hearing. Type of OAC prescribed was documented in medical records. Results: 86% of participants were prescribed an OAC. These participants were on average aged 75.7 (SD: 7.1) years, 49% were women, two thirds were frail or pre-frail, and 44% received a DOAC. DOAC users were younger, had lower CHA2DS2VASC and HAS-BLED scores, and were less likely to be frail. In Massachusetts, pre-frailty was associated with a significantly lower odds of DOAC vs. VKA use (OR = 0.64, 95%CI 0.45, 0.91). Pre-frailty (OR = 0.33, 95%CI 0.18-0.59) and social isolation (OR = 0.38, 95%CI 0.14-0.99) were associated with lower odds of DOAC receipt in patients aged 75 years or older. Social isolation was associated with higher odds of DOAC use (OR = 2.13, 95%CI 1.05-4.29) in patients aged 65-74 years. Conclusions: Geriatric conditions were common and related to type of OAC prescribed, differentially by age group. Research is needed to evaluate whether a geriatric examination can be used clinically to better inform OAC decision-making in older patients with AF.

13.
JCI Insight ; 4(22)2019 11 14.
Article de Anglais | MEDLINE | ID: mdl-31622279

RÉSUMÉ

Cardiomyopathies are complex heart muscle diseases that can be inherited or acquired. Dilated cardiomyopathy can result from mutations in LMNA, encoding the nuclear intermediate filament proteins lamin A/C. Some LMNA mutations lead to accumulation of the lamin A precursor, prelamin A, which is disease causing in a number of tissues, yet its impact upon the heart is unknown. Here, we discovered myocardial prelamin A accumulation occurred in a case of dilated cardiomyopathy, and we show that a potentially novel mouse model of cardiac-specific prelamin A accumulation exhibited a phenotype consistent with inflammatory cardiomyopathy, which we observed to be similar to HIV-associated cardiomyopathy, an acquired disease state. Numerous HIV protease therapies are known to inhibit ZMPSTE24, the enzyme responsible for prelamin A processing, and we confirmed that accumulation of prelamin A occurred in HIV+ patient cardiac biopsies. These findings (a) confirm a unifying pathological role for prelamin A common to genetic and acquired cardiomyopathies; (b) have implications for the management of HIV patients with cardiac disease, suggesting protease inhibitors should be replaced with alternative therapies (i.e., nonnucleoside reverse transcriptase inhibitors); and (c) suggest that targeting inflammation may be a useful treatment strategy for certain forms of inherited cardiomyopathy.


Sujet(s)
Cardiomyopathie dilatée , Infections à VIH , Inflammation/métabolisme , Lamine A , Adulte , Animaux , Cardiomyopathie dilatée/métabolisme , Cardiomyopathie dilatée/virologie , Modèles animaux de maladie humaine , Femelle , Infections à VIH/complications , Infections à VIH/métabolisme , Coeur/physiopathologie , Humains , Lamine A/génétique , Lamine A/métabolisme , Mâle , Souris , Adulte d'âge moyen , Myocarde/métabolisme , Myocarde/anatomopathologie
14.
J Cardiovasc Electrophysiol ; 30(11): 2508-2515, 2019 11.
Article de Anglais | MEDLINE | ID: mdl-31515920

RÉSUMÉ

BACKGROUND: Successful anticoagulation is critical for stroke prevention in adults with atrial fibrillation (AF). Anticoagulation satisfaction is a key indicator of treatment success. While physical, cognitive, and psychosocial limitations are common in elderly AF patients, their associations with anticoagulation satisfaction are unknown. OBJECTIVE: Examine whether anticoagulation satisfaction differs among AF patients with and without physical, cognitive, and psychosocial conditions. METHODS: The study comprised AF patients greater than or equal to 65 years old who were prescribed an oral anticoagulant (warfarin 57%; direct oral anticoagulant [DOAC] 43%). Frailty, cognitive function, social support, depressive symptoms, vision, hearing, and anxiety were assessed using validated measures. Anticoagulation satisfaction was measured using the anticlot treatment scale. RESULTS: Participants (n = 1037, 50% female) were on average 76 years old. The following conditions were prevalent: frailty (14%), cognitive impairment (42%), social isolation (13%), vision impairment (35%), hearing impairment (36%), depression (29%), and anxiety (24%). Average anticlot treatment burden scale was 55 out of 60 (lower burden scales indicating higher perceived burden). Patients with high perceived burden were older, more likely to be female, and receive warfarin. After adjusting for confounders, visual impairment (adjusted odds ratio [95% confidence interval]: 1.7 [1.2-2.4]), depressive symptoms (2.4 [1.6-3.7]), and anxiety (1.8 [1.2-2.7]) were significantly associated with high perceived burden. Different conditions were associated with high perceived burden in warfarin vs DOAC users. CONCLUSION: Physical, cognitive, and psychosocial limitations are prevalent and associated with high perceived anticoagulation burden among elderly AF adults. These conditions merit consideration in anticoagulation prescribing.


Sujet(s)
Anticoagulants/administration et posologie , Fibrillation auriculaire/traitement médicamenteux , Cognition , Fragilité/diagnostic , Évaluation gériatrique , Santé mentale , Satisfaction des patients , Accident vasculaire cérébral/prévention et contrôle , Administration par voie orale , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Anticoagulants/effets indésirables , Anxiété/diagnostic , Anxiété/épidémiologie , Anxiété/psychologie , Fibrillation auriculaire/diagnostic , Fibrillation auriculaire/épidémiologie , Comorbidité , Études transversales , Dépression/diagnostic , Dépression/épidémiologie , Dépression/psychologie , Femelle , Personne âgée fragile , Fragilité/épidémiologie , Fragilité/physiopathologie , Fragilité/psychologie , Géorgie/épidémiologie , Humains , Mâle , Massachusetts/épidémiologie , Prévalence , Facteurs de risque , Facteurs sexuels , Soutien social , Accident vasculaire cérébral/diagnostic , Accident vasculaire cérébral/épidémiologie , Résultat thérapeutique , Troubles de la vision/diagnostic , Troubles de la vision/épidémiologie , Troubles de la vision/physiopathologie
15.
J Am Heart Assoc ; 8(16): e012595, 2019 08 20.
Article de Anglais | MEDLINE | ID: mdl-31423885

RÉSUMÉ

Background Heart failure (HF) admissions in adults with congenital heart disease (CHD) are becoming more common. We compared in-hospital and readmission events among adults with and without CHD admitted for HF. Methods and Results We identified all admissions with the primary diagnosis of HF among adults in the California State Inpatient Database between January 1, 2005 and January 1, 2012. International Classification of Disease (ICD) codes identified the type of CHD lesion, comorbidities, and in-hospital and 30-day readmissions events. Adjusted odds ratio (AOR, 95% CI) was calculated after adjusting for admission year, age, sex, race, household income, primary payor, and Charlson comorbidity index. Of 203 759 patients admitted for HF, 539 had CHD other than atrial septal defect. Compared with patients admitted for HF without CHD, those with CHD were younger, more often male, and had fewer comorbidities as determined by Charlson comorbidity index. On multivariate analysis, CHD patients admitted for HF had higher odds of length of stay ≥7 days (AOR 2.5 [95% CI 2.0-3.1]), incident arrhythmias (AOR 2.8 [95% CI 1.7-4.5]), and in-hospital mortality (AOR 1.9 [95% CI 1.1-3.1]). Also, CHD patients had lower odds of readmission for HF (AOR 0.6 [95% CI 0.3-0.9]), but similar odds of other 30-day readmission events. Complex CHD patients had higher odds of length of stay ≥7 days (AOR 1.9 [95% CI 1.1-3.3]) than patients with noncomplex CHD lesions, but similar odds of all other clinical outcomes. Conclusions Among patients admitted with the primary diagnosis of HF in California, adults with CHD have substantially higher odds of longer length of stay, incident arrhythmias, and in-hospital mortality compared with non-CHD patients. These results suggest a need for HF risk stratification strategies and management protocols specific for patients with CHD.


Sujet(s)
Troubles du rythme cardiaque/épidémiologie , Défaillance cardiaque/thérapie , Mortalité hospitalière , Durée du séjour/statistiques et données numériques , Adolescent , Adulte , Sujet âgé , Californie/épidémiologie , Comorbidité , Femelle , Cardiopathies congénitales/complications , Défaillance cardiaque/complications , Humains , Incidence , Mâle , Adulte d'âge moyen , Odds ratio , Réadmission du patient/statistiques et données numériques , Jeune adulte
16.
Cell Rep ; 27(11): 3124-3138.e13, 2019 06 11.
Article de Anglais | MEDLINE | ID: mdl-31189100

RÉSUMÉ

Biomineralization of the extracellular matrix is an essential, regulated process. Inappropriate mineralization of bone and the vasculature has devastating effects on patient health, yet an integrated understanding of the chemical and cell biological processes that lead to mineral nucleation remains elusive. Here, we report that biomineralization of bone and the vasculature is associated with extracellular poly(ADP-ribose) synthesized by poly(ADP-ribose) polymerases in response to oxidative and/or DNA damage. We use ultrastructural methods to show poly(ADP-ribose) can form both calcified spherical particles, reminiscent of those found in vascular calcification, and biomimetically calcified collagen fibrils similar to bone. Importantly, inhibition of poly(ADP-ribose) biosynthesis in vitro and in vivo inhibits biomineralization, suggesting a therapeutic route for the treatment of vascular calcifications. We conclude that poly(ADP-ribose) plays a central chemical role in both pathological and physiological extracellular matrix calcification.


Sujet(s)
Biominéralisation , Altération de l'ADN , Poly adénosine diphosphate ribose/métabolisme , Calcification vasculaire/métabolisme , Adolescent , Adulte , Sujet âgé , Animaux , Vaisseaux sanguins/métabolisme , Vaisseaux sanguins/anatomopathologie , Bovins , Lignée cellulaire , Cellules cultivées , Collagène/métabolisme , Matrice extracellulaire/métabolisme , Femelle , Humains , Mâle , Souris , Adulte d'âge moyen , Ostéoblastes/métabolisme , Ostéoblastes/anatomopathologie , Stress oxydatif , Rats , Rat Wistar , Ovis
17.
Chem Commun (Camb) ; 54(89): 12570-12573, 2018 Nov 06.
Article de Anglais | MEDLINE | ID: mdl-30299444

RÉSUMÉ

The sparse but functionally essential post-translational collagen modification 5-hydroxylysine can undergo further transformations, including crosslinking, O-glycosylation, and glycation. Dynamic nuclear polarization (DNP) and stable isotope enriched lysine incorporation provide sufficient solid-state NMR sensitivity to identify these adducts directly in skin and vascular smooth muscle cell extracellular matrix (ECM), without extraction procedures, by comparison with chemical shifts of model compounds. Thus, DNP provides access to the elucidation of structural consequences of collagen modifications in intact tissue.

18.
J Atr Fibrillation ; 10(5): 1749, 2018 Feb.
Article de Anglais | MEDLINE | ID: mdl-29988239

RÉSUMÉ

BACKGROUND: Atrial fibrillation (AF) is a common complication of acute myocardial infarction (AMI).The CHA2DS2VAScand CHADS2risk scoresare used to identifypatients with AF at risk for strokeand to guide oral anticoagulants (OAC) use, including patients with AMI. However, the epidemiology of AF, further stratifiedaccording to patients' risk of stroke, has not been wellcharacterized among those hospitalized for AMI. METHODS: We examined trends in the frequency of AF, rates of discharge OAC use, and post-discharge outcomes among 6,627 residents of the Worcester, Massachusetts area who survived hospitalization for AMI at 11 medical centers between 1997 and 2011. RESULTS: A total of 1,050AMI patients had AF (16%) andthe majority (91%)had a CHA2DS2VAScscore >2.AF rates were highest among patients in the highest stroke risk group.In comparison to patients without AF, patients with AMI and AF in the highest stroke risk category had higher rates of post-discharge complications, including higher 30-day re-hospitalization [27 % vs. 17 %], 30-day post-discharge death [10 % vs. 5%], and 1-year post-discharge death [46 % vs. 18 %] (p < 0.001 for all). Notably, fewerthan half of guideline-eligible AF patientsreceived an OACprescription at discharge. Usage rates for other evidence-based therapiessuch as statins and beta-blockers,lagged in comparison to AMI patients free from AF. CONCLUSIONS: Our findings highlight the need to enhance efforts towards stroke prevention among AMI survivors with AF.

19.
Am J Cardiol ; 122(5): 799-805, 2018 09 01.
Article de Anglais | MEDLINE | ID: mdl-30053999

RÉSUMÉ

Cardiac devices are increasingly an element of treatment for the elderly, leading to more frequent transvenous lead removal (TLR) procedures in this population. Data on TLR in very elderly patients, especially nonagenarians, is scarce. We used Healthcare Cost and Utilization Project Nationwide Inpatient Sample to identify a total of 36,099 patients ≥70 years who underwent TLR from 2005 to 2012, with outcomes including in-hospital mortality and complications. The in-hospital mortality rate was significantly higher in nonagenarians without device infection (0.9% in age 70 to 79 vs 0.7% in age 80 to 89 vs 2.6% in age ≥90, p = 0.012), but overall complication rates were not different in age groups regardless of infection status and co-morbidity index (all p >0.05). Among patients with device infection, octogenarians, and nonagenarians were not associated with increased risk of in-hospital mortality relative to septuagenarians after controlling for all other confounders. However, in patients without device infection, logistic regression showed significantly higher mortality in patients age ≥90 years (odd ratio 4.22, 95% confidence interval 1.66 to 10.75, p = 0.003), but not in patients age 80 to 89 years (odd ratio 1.05, 95% confidence interval 0.48 to 2.30, p = 0.907), compared with patients age 70 to 79 years. In conclusion, in nonagenarians with infection, mortality is driven more by the patient's other conditions than by age. For patients without infection, however, nonagenarians experienced higher mortality than younger patients.


Sujet(s)
Défibrillateurs implantables/effets indésirables , Ablation de dispositif , Pacemaker/effets indésirables , Sécurité des patients , Sujet âgé , Sujet âgé de 80 ans ou plus , Études transversales , Femelle , Mortalité hospitalière , Humains , Mâle , États-Unis
20.
Circulation ; 137(2): 166-183, 2018 01 09.
Article de Anglais | MEDLINE | ID: mdl-29030347

RÉSUMÉ

BACKGROUND: Extracellular matrix (ECM) remodeling contributes to in-stent restenosis and thrombosis. Despite its important clinical implications, little is known about ECM changes post-stent implantation. METHODS: Bare-metal and drug-eluting stents were implanted in pig coronary arteries with an overstretch under optical coherence tomography guidance. Stented segments were harvested 1, 3, 7, 14, and 28 days post-stenting for proteomics analysis of the media and neointima. RESULTS: A total of 151 ECM and ECM-associated proteins were identified by mass spectrometry. After stent implantation, proteins involved in regulating calcification were upregulated in the neointima of drug-eluting stents. The earliest changes in the media were proteins involved in inflammation and thrombosis, followed by changes in regulatory ECM proteins. By day 28, basement membrane proteins were reduced in drug-eluting stents in comparison with bare-metal stents. In contrast, the large aggregating proteoglycan aggrecan was increased. Aggrecanases of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family contribute to the catabolism of vascular proteoglycans. An increase in ADAMTS-specific aggrecan fragments was accompanied by a notable shift from ADAMTS1 and ADAMTS5 to ADAMTS4 gene expression after stent implantation. Immunostaining in human stented coronary arteries confirmed the presence of aggrecan and aggrecan fragments, in particular, at the contacts of the stent struts with the artery. Further investigation of aggrecan presence in the human vasculature revealed that aggrecan and aggrecan cleavage were more abundant in human arteries than in human veins. In addition, aggrecan synthesis was induced on grafting a vein into the arterial circulation, suggesting an important role for aggrecan in vascular plasticity. Finally, lack of ADAMTS-5 activity in mice resulted in an accumulation of aggrecan and a dilation of the thoracic aorta, confirming that aggrecanase activity regulates aggrecan abundance in the arterial wall and contributes to vascular remodeling. CONCLUSIONS: Significant differences were identified by proteomics in the ECM of coronary arteries after bare-metal and drug-eluting stent implantation, most notably an upregulation of aggrecan, a major ECM component of cartilaginous tissues that confers resistance to compression. The accumulation of aggrecan coincided with a shift in ADAMTS gene expression. This study provides the first evidence implicating aggrecan and aggrecanases in the vascular injury response after stenting.


Sujet(s)
Protéines ADAMTS/métabolisme , Agrécanes , Vaisseaux coronaires/chirurgie , Endopeptidases/métabolisme , Matrice extracellulaire/enzymologie , Intervention coronarienne percutanée/instrumentation , Protéomique/méthodes , Endoprothèses , Remodelage vasculaire , Protéines ADAMTS/génétique , Protéine ADAMTS5/génétique , Protéine ADAMTS5/métabolisme , Animaux , Chromatographie en phase liquide à haute performance , Vaisseaux coronaires/enzymologie , Vaisseaux coronaires/physiopathologie , Endoprothèses à élution de substances , Endopeptidases/génétique , Femelle , Humains , Mâle , Métaux , Souris knockout , Modèles animaux , Néointima , Conception de prothèse , Transduction du signal , Sus scrofa , Spectrométrie de masse en tandem , Facteurs temps
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE